US CORP PURCHASED A MAJORITY OF THE SHARES IN AURA BIOPHARM AS
US CORP, A US biotechnology corporation has purchased a majority of the shares in AURA Biopharm AS.
AURA Biopharm AS is a Norwegian Biotechnology company founded by a team of international scientists and drug developers. The company has exclusive rights to the product AUR-1001, which is a first-in-class pathogenic-tailored drug for the prevention of thrombosis and fetal loss in patients with antiphospholipid syndrome.
The US Corp is lead by proven biopharmaceutical executives, and is committed to the development of AURA’s AUR-1001. There is great excitement to work with the AURA team to develop this product.
Dr. Olav Flaten, chairman and CEO of AURA Biopharm AS, says this is a great opportunity for AURA and for the development of the company’s lead compound AUR-1001. It also demonstrates that AURA is internationally recognized for the discovery and development of a biologic compound to address an illness with a high medical need.